6:21 PM
 | 
Jun 11, 2007
 |  BC Extra  |  Company News

Archemix in pair of aptamer deals

Archemix ( Cambridge, Mass.) announced two separate deals with Merck KGaA (FSE:MRK) and Takeda (Tokyo:4502) for aptamer therapeutics. With MRK, Archemix will use its SELEX technology to discover aptamer candidates for six undisclosed targets from either company for cancer,...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >